fashion -WSS

fashion

author：comprehensive 2025-09-27 23:53:47 - browse：321

Robert F. Kennedy Jr. said Tuesday that he will head up a panel on vaccine safety for Donald Trump.

The president-elect’s transition team spokeswoman later walked that back, saying that he is “exploring the possibility” of forming a panel on autism, but “no decisions have been made.”

Let’s hope Trump drops any idea of a vaccine panel headed by Kennedy. For more than a decade, Kennedy has promoted anti-vaccine propaganda completely unconnected to reality. If Kennedy’s panel leads to even a small decline in vaccine rates across the country, it will result in the waste of untold amounts of money and, in all likelihood, the preventable deaths of infants too young to be vaccinated.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： Readout Newsletter: The latest on Moderna, Apellis, and Merck

WSS

Bristol Myers buys into radiopharmaceuticals with RayzeBio

ALS groups 'won't be played again' by the FDA, drug sponsors

Editas, Vertex strike deal on CRISPR

What STAT readers think about the FDA and patient advocacy

Grail spinoff by Illumina should end disastrous merger attempt

House looks to weaken Medicare negotiation

leisure time

fashion

leisure time

Continuity nursing helped my family in our darkest PICU moments

Why getting cancer drugs just got harder for rural patients

DIEP, the 'gold standard' of breast reconstruction, is under threat

In search for therapies for solid tumors, companies turn to claudin

Psychedelics group wrestles with new pharma identity

Scientists unlock the key to scar

Apple is now the first public company to be valued at $3 trillion

Scientists unlock the key to scar

Sports medicine is finally prioritizing gender equality

Covid isolation guidance eased by the CDC

entertainment

David Ricks of Eli Lilly: best biopharma CEO of 2023

Pfizer highlights cancer drugs it thinks could reignite investor interest

FogPharma raises $145 million in rare Series E round

How to keep neuroscience’s past racism from being its future

Medicare Advantage beneficiaries sue Humana over algorithm use

Humana’s Medicare Advantage lawsuit should be tossed, DOJ says

hotspot

focus

focus

entertainment